Renaistre Scientific
20+ years. 35 FDA-approved cancer therapies. One firm that has been on both sides of every decision your program will face — and can help you make the right ones.
Areas of Expertise
Preclinical Pharmacology
Expert study design and execution across in vitro and in vivo models, with deep oncology focus and IND-enabling program oversight.
AI Drug Development
AI tools consultation, platform evaluation, target dataset due diligence, vendor benchmarking, IP strategy, partnership advisory, and commercialization guidance.
Business Development
In/out-licensing, partnership identification, deal structuring, M&A advisory, alliance management, due diligence, commercial org design, KPI frameworks, and market access.
Scientific Operations
Preclinical CRO-focused vendor selection, study design oversight, contract negotiation, in-life monitoring, data review, cross-CRO coordination, and IND-readiness gap analysis.
We bring two decades of hands-on drug development experience to every engagement — from target identification through IND submission and beyond. Our founder has contributed to programs resulting in 35 FDA-approved cancer therapies.
Our Story→35 FDA-Approved Programs
Our founder contributed to the R&D programs behind 35 FDA-approved cancer therapies — including blockbuster cancer drugs Rasonque, Pluvicto, Keytruda, Opdivo, Kadcyla, Darzalex, and Tagrisso. Our advice is grounded in a track record most consultants can't match.
Both Sides of the Table
We've successfully operated in leadership roles spanning scientific operations, scientific oversight, strategic market development, corporate development, and business development divisions within 4 major preclinical drug development CROs — everything from lab-bench work, to designing studies, to establishing strategic partnerships, to designing and securing transformational multi-million-dollar deals. That insider perspective — from the bench to the boardroom — is what separates our recommendations from generalist consulting.
Genuinely Independent
No vendor relationships. No referral arrangements. No financial ties to the platforms or CROs we evaluate. Our advice is shaped entirely by what is right for your program.
Ready to accelerate your program?
Whether you need preclinical expertise, AI strategy, or business development support — we're ready to partner with you.
Found this useful? Share it with your network.